Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

1437 - A critical appraisal of quality indicators of breast cancer treatment in Belgium


29 Sep 2019


Poster Display session 2


Tumour Site

Breast Cancer


Didier Verhoeven


Annals of Oncology (2019) 30 (suppl_5): v55-v98. 10.1093/annonc/mdz240


D.M.E.C. Verhoeven1, F.P. Duhoux2, E. de Azambuja3, L. van Walle4, K. Punie5, H. Wildiers5, P. Vuylsteke6, A. Barbeaux7, N. Van Damme8, L. Van Eycken9

Author affiliations

  • 1 Medical Oncology, University of Antwerp, 2000 - Antwerpen/BE
  • 2 Medical Oncology, Cliniques universitaires Saint-Luc, UCLouvain, 1200 - Brussels/BE
  • 3 Medical Onology, Institute Jules Bordet, 1000 - Brussels/BE
  • 4 Registry, Belgian Cancer Registry, Brussels/BE
  • 5 Medical Oncology, University Hospitals Leuven - Campus Gasthuisberg, 3000 - Leuven/BE
  • 6 Department Of Oncology, CHU-UCL-Namur Clinique Ste Elisabeth, UCLouvain, 5000 - Namur/BE
  • 7 Medical Oncology, CHR Verviers, 4800 - Verviers/BE
  • 8 Registry, Belgian Cancer Registry, 1000 - Brussels/BE
  • 9 Registry, Belgian Cancer Registry, 1210 - Brussels/BE


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1437


A task force was created by the Belgian Society of Medical Oncology (BSMO) to monitor the quality of treatment of breast cancer in Belgium. In collaboration with the Belgian Cancer Registry an analysis of the data was performed in search of reliable quality indicators. Finding actionable differences can lead to better treatment of our patients.


Data of 48,872 patients diagnosed with invasive breast cancer between 2010 and 2014 were analysed. To enable risk stratification according to their surrogate subtype, pathology reports of year 2014 were manually checked (9,855 patients). We identified patients < 70 Y (years) and > 75 Y receiving adjuvant radiotherapy after mastectomy and the different systemic treatments in each surrogate subtype. We also calculated the total length of endocrine treatment and the percentage of chemotherapy given in first line ER+ metastatic patients.


In cStage I-III, post-mastectomy radiotherapy was administered in 70.7% of the patients <70 Y and in 46.5% of patients > 75 Y, with an important intercenter variability. 81.7% of the cStage I-III patients <70 Y received at least 4.5 years of adjuvant endocrine therapy, with a slight decrease each year. In the 2014 cohort we identified 54.4% luminal A-like, 14.9% luminal B-like HER2-, 12.4% luminal B-like HER2+, 4.6% non luminal HER2+, 8.6% triple negative and 5.1% unknown. As a negative indicator, 44.6% of the HER2+ pT1aN0 patients <70 Y received adjuvant trastuzumab, compared to 22.2% of the patients > 70 Y. As first treatment for cStage IV HR+/HER2- patients, we identified endocrine therapy in 53.9% and chemotherapy in 17.3%.


Substantial treatment differences were observed among centers. Overtreatment is an important negative quality aspect of breast cancer management. A frequent use of postmastectomy radiotherapy was observed. The use of trastuzumab was inappropriate in pT1aN0 patients. Chemotherapy was used too often in first line hormone receptor positive metastatic patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Belgian Cancer Registry.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.